UNSPSC 51452101: Hexylresorcinol

This classification denotes a topical anti-infective agent with the molecular formula C12H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9QTB5E82N, chemically known as 1,3-dihydroxy-4-n-hexylbenzene but generally known as 4-hexylresorcinol, which bears US NIH Compound Identifier 3610. European Medicines Agency schedules Hexylresorcinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14103MIG.

World Health Organization schedules 4-hexylresorcinol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, HEXYLRESORCINOL remains the US FDA Preferred Term for this commodity. Hexylresorcinol bears US NLM identifiers UMLS ID C0019497 and NCI Concept Code C29092. SMILES: CCCCCCC1=C(C=C(C=C1)O)O.

UNSPSC 51452101 Hexylresorcinol is a Commodity code that spans pharmaceutical chemical agents and active pharmaceutical ingredients procured by state and local health departments and county health systems. Recent state and local solicitations under this code show little activity directly matching hexylresorcinol itself; instead, issuing bodies are purchasing finished pharmaceutical products and medical countermeasures including antibiotics, opioid antagonists, and drug disposal systems for public health stockpiles and community health programs. The Illinois Department of Public Health and Seminole County, Florida represent the issuing-body types visible in recent records — state health agencies and county health departments — though the posted opportunities reflect broader pharmaceutical procurement vehicles and piggyback contracts rather than hexylresorcinol-specific sourcing.

Geographic activity appears concentrated in Florida and Illinois based on recent postings. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 totaling $2,999,999.11 over the contract life (12 months plus two one-year renewal options) for antibiotic tablets under an IFB process. Seminole County, Florida released an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with a July 26, 2026 response deadline, though that opportunity reflects naloxone procurement rather than hexylresorcinol sourcing. The code shows limited recent activity specifically tied to hexylresorcinol availability or demand signals in the state and local market.